Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations

被引：1
|
作者：
Safra, T.
Borgato, L.
Nicoletto, M.
Rolnitzky, L.
Curtin, J.
Geva, R.
Peles, S.
Grenader, T.
Gabizon, A.
Muggia, F.
机构：
[1] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel
[2] IOV, Padua, Italy
[3] NYU Med Ctr, New York, NY 10016 USA
[4] SZMC, Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5043
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Implications of BRCA mutations on recurrent ovarian cancer outcome treated with pegylated liposomal doxorubicin (PLD)
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Donach, Martin Edward
    Rolnitzky, Linda
    Geva, Ravit
    Peles, Sharon
    Pua, Thara
    Novetsky, Akiva
    Gabizon, Alberto
    Muggia, Franco
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [2] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
    Muggia, F.
    Safra, T.
    Borgato, L.
    Gandhi, A.
    Mancinc, G.
    Gabizon, A.
    Liebes, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer [REOC).
    Grenier, N
    Lebel, V
    Gill, M
    Mitchinson, K
    Foster, M
    Lewis, S
    Sebborn, K
    Rodgers, A
    Pouliot, JF
    Mullen, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 778S - 778S
  • [4] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [5] Treatment-related microangiopathic glomerulopathy and severe chronic kidney disease (CKD) in recurrent epithelial ovarian cancer (rEOC): A possible relationship with pegylated liposomal doxorubicin (PLD).
    Kwa, M.
    Baumgartner, R. A.
    Shavit, L.
    Barash, I.
    Michael, J.
    Puzanov, I.
    Kopolovic, J.
    Rosengarten, O.
    Hung, A.
    Jones, H.
    Gabizon, A.
    Muggia, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Efficacy and toxicity of extended duration pegylated liposomal doxorubicin (PLD) in women with recurrent epithelial ovarian cancer
    Chambers, L. Moulton
    Pendlebury, A. B.
    Yao, M.
    Rose, P. G.
    DeBernardo, R.
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 107 - 108
  • [7] Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, Gurbuz
    Kucukzeybek, Yuksel
    Karabulut, Bulent
    Terek, Mustafa C.
    Uslu, Ruchan
    Sanli, Ulus A.
    Akman, Levent
    Ozsaran, Aydin
    Dikmen, Yilmaz
    Goker, Erdem
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [8] Pegylated liposomal Doxorubicin in Recurrent Ovarian Cancer
    Lorenz, Judith
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (11)
  • [9] BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Rolnitzky, Linda
    Pelles-Avraham, Sharon
    Geva, Ravit
    Donach, Martin Edward
    Curtin, John
    Novetsky, Akiva
    Grenader, Tal
    Lai, Wei-Chu V.
    Gabizon, Alberto
    Boyd, Leslie
    Muggia, Franco
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (10) : 2000 - 2007
  • [10] Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
    Monk, Bradley J.
    Herzog, Thomas J.
    Kaye, Stanley B.
    Krasner, Carolyn N.
    Vermorken, Jan B.
    Muggia, Franco M.
    Pujade-Lauraine, Eric
    Park, Youn C.
    Parekh, Trilok V.
    Poveda, Andres M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (15) : 2361 - 2368
12345